Mechanism, stoichiometry, and specificity
Food and Drug Administration (2025)
Daraxonrasib , made by Revolution Medicines, has changed that: it first binds a scaffolding protein (called Cyclophilin A) and then RAS, which locks it into an inactive state: This mechanism means that Daraxonrasib inhibits many of the major RAS mutations: Pancreatic cancer is addicted to this continuous RAS activity so if its inhibited, tumours should shrink
However, using a more stringent inclusion criteria, we identified one well-characterized protein of interest that was both significantly altered in abundance and displayed a large reduction in signal for those affected with konzo, Glutathione Peroxidase 3 (GPx3)
Preclinical studies demonstrate improvements in tendon-to-bone healing, with enhanced collagen organization and increased tensile strength in healed tissues
This ensures that what is on the label is actually in the bottle and that the product is free from heavy metals, mold, and synthetic fillers